Aytu BioPharma Inc. (NASDAQ:AYTU) Receives $9.33 Average Target Price from Brokerages

Aytu BioPharma Inc. (NASDAQ:AYTU) has been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $9.3333.

Several equities analysts have recently commented on AYTU shares. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Wall Street Zen upgraded Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Ascendiant Capital Markets lifted their target price on Aytu BioPharma from $12.50 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a report on Friday, January 9th.

Aytu BioPharma Stock Down 3.8%

Shares of AYTU stock opened at $2.54 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.16 and a quick ratio of 1.03. Aytu BioPharma has a one year low of $0.95 and a one year high of $3.07. The company’s fifty day moving average price is $2.53 and its 200-day moving average price is $2.35. The company has a market capitalization of $27.25 million, a price-to-earnings ratio of -0.66 and a beta of 0.35.

Aytu BioPharma (NASDAQ:AYTU) last issued its earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.The firm had revenue of $15.17 million during the quarter, compared to the consensus estimate of $12.17 million.

Hedge Funds Weigh In On Aytu BioPharma

Hedge funds have recently modified their holdings of the stock. AWM Investment Company Inc. bought a new position in shares of Aytu BioPharma during the second quarter worth $1,351,000. Stonepine Capital Management LLC increased its holdings in Aytu BioPharma by 75.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock valued at $1,772,000 after acquiring an additional 348,955 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in Aytu BioPharma in the 3rd quarter worth $117,000. Bellevue Asset Management LLC purchased a new stake in Aytu BioPharma in the 4th quarter worth $65,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma during the 3rd quarter valued at about $58,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.